Effect of Luteolin Supplementation on Kidney Damage and Long-Term Prognosis in Diabetic Patients: A Cohort Study.

Luteolin intake dosage was an independent influencing factor for kidney damage prevalence in diabetes.

• Analysis was performed using logistic regression to examine the relationship between flavonoid intake dosage and kidney damage prevalence.
• A total of 2591 diabetic participants were included from the NHANES database.
• Covariates adjusted in multivariate analysis included gender, age, ethnicity, education level, marital status, BMI, SBP, HbA1c, smoking status, alcohol intake, and hypertension prevalence.

Diabetic patients in the high Luteolin intake group had a lower prevalence of kidney damage compared to those in the low Luteolin intake group.

• Participants were stratified into Luteolin-high and Luteolin-low intake groups for comparison.
• Flavonoid intake data were extracted from the FNDDS Flavonoid database.
• The finding was based on preliminary logistic regression analysis adjusted for multiple covariates.

The urinary microalbumin to urinary creatinine ratio (UACR) was significantly lower in the high Luteolin intake group compared to the low Luteolin intake group.

• UACR is used as a marker of kidney damage in diabetic patients.
• The difference in UACR between the high and low Luteolin intake groups was described as statistically significant.
• This finding supports the association between higher Luteolin intake and reduced kidney damage.

Every 1 mg/d increase in Luteolin intake was associated with a 14.2% decrease in mortality among diabetic patients.

• HR = 0.858, 95% CI: 0.744–0.990, p = 0.036.
• The median follow-up time was 121 months.
• Mortality information was extracted from the 2019 public-use linked mortality files provided by the NCHS.
• Cox regression analysis was used to investigate whether Luteolin supplementation positively affected survival probability, with Kaplan-Meier survival curves also employed.